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Summary
Background: Malignant pleural effusion is a common problem in advanced cancers, contributing to the
poor quality of life in this group of patients. The aim of the study was to assess the efficiency
of talc powder and doxycycline in pleurodesis in patients with malignant pleural effusion in
comparable conditions.
Material/Methods: Of 52 patients screened, 33 entered the trial. They were randomized to the talc group (n=18)
and the doxycycline group (n=15). Both groups were comparable with regard to age, sex and
the most important variables influencing effectiveness of the procedure, i.e. primary malig-
nancy and stage of metastatic involvement of the pleura. Efficiency of pleurodesis was
prospectively assessed.
Results: The analysis of short-term effectiveness of pleurodesis in the first 33 patients has shown a
highly significant difference in favor of talc powder (p=0.009); this difference was the reason
for terminating the randomization. Further observation has revealed in the doxycycline
group an increasing number of patients with fluid reaccumulation, as time went by; this was
not observed in the talc group. A statistical analysis of the long-term effectiveness of both
agents studied has shown a more significant difference in favor of the talc powder
(p=0.00003).
Conclusions: Talc powder is superior to doxycycline in achieving pleurodesis in patients with malignant
pleural effusion, in both short- and long-term observations.
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BACKGROUND
Malignant pleural effusion is a common problem in
advanced cancers, contributing to the poor quality of
life in this group of patients. The palliative treatment of
choice is obliteration of the pleural space to prevent
fluid accumulation (pleurodesis). There is a large body
of evidence, that talc and doxycycline are two of the
most effective sclerosing agents in treatment of malig-
nant pleural effusions [1–13]. Most trials suggest slightly
better effectiveness of talc (76–94.5%) [1–9] over doxycy-
cline (79–88%) [10–13], but the differences are not sig-
nificant, and the route of administration of the agent
varies in most publications. In fact, talc powder was usu-
ally administered during thoracoscopy, and doxycycline
via a chest tube. Instillation of doxycycline via a chest
tube implies an inability to assess the degree of involve-
ment of the pleura. As the advancement of the metastat-
ic process on the surface of the pleura is associated with
an increased risk of failure of pleurodesis, [14] the com-
parison of the effectiveness of talc and doxycycline may
be biased by incomparability of the groups studied.
To assess the efficiency of talc powder and doxycycline
in comparable conditions we designed a prospective,
randomized study using videothoracoscopy.
MATERIAL AND METHODS
We screened all patients admitted to the Division of
Interventional Pulmonology of the University Hospital
in Cracow with pleural effusion and clinical suspicion of
malignant origin. The excluding criteria were as fol-
lows:
1) failure to confirm malignancy in the pleura by macro-
scopic assessment in videothoracoscopy and histologi-
cal examination of parietal pleura specimens;
2) establishing the diagnosis of the malignant pleural
mesothelioma;
3) inability to achieve full re-expansion of the lung.
From October 1998 to December 2000, a group of 52
patients was examined for the study. In this group, 19
patients met at least one of the excluding criteria: in 3
the metastatic disease to the pleura was not confirmed,
in 14 the diagnosis of malignant pleural mesothelioma
was made, and in 2 we were unable to achieve full re-
expansion of the lung. The study was terminated before
including the planned number of 100 patients, because
the initial analysis had shown a statistically highly signif-
icant difference of effectiveness in favor of talc powder.
Further randomization would therefore be ethically
unacceptable. Thus the data of 33 patients were finally
analyzed.
The patients included were randomly assigned to one of
the two groups: in the first group, 10 g of talc powder
was insufflated on the whole surface of the pleura with a
hand insufflator, and in the second group 500 mg doxy-
cycline in 25 ml solution was instilled to the pleural cavi-
ty. Videothoracoscopy was used to assess the stage of
metastatic involvement of the pleura and to take biopsy
specimens allowing for a histopathological diagnosis.
Previous experience at our institution indicates that
there is a constant pattern of involvement of the pleura
in the metastatic process. Nodular metastatic foci
appear always in the same sequence: first, on the lower
part of the parietal pleura, then on the upper, and in
the more advanced cases on the visceral pleura. We
found no exceptions to this rule in 110 patients in
whom we had previously performed videothoracoscopy.
However, in 5 cases the spreading of cancer had anoth-
er pattern: in contrast to nodular dissemination, we
observed a wide, flat infiltration of great areas of pari-
etal and visceral pleura, with lung entrapment and mul-
tilocular fluid collection formation. In this later group,
the macroscopic view mimics parapneumonic effusion
and the cancer spreads aggressively, leading in a short
time to the patient’s death.
On the basis of the experience described above, we
developed an abbreviated system of staging metastatic
involvement of the pleura (table 1).
Videothoracoscopy was performed under general anes-
thesia. The patients were intubated with a Robertshaw-
type tracheal tube allowing separate ventilation of one
lung; they were placed in lateral decubitus position with
a roll under the flank and the upper arm abduced. We
used a rigid 10 mm thoracoscope. The placement of the
first port was selected after analysis of chest X-ray
and/or CT scans, usually in the 5th intercostal space in
the midaxillary line. After needle aspiration to confirm
the presence of fluid, the first port was introduced and
initial inspection of the pleural cavity was performed.
Under visual control we introduced the second (5 mm)
port to remove all the fluid by suction (the fluid was col-
lected for cytological examination). After the fluid had
been removed, we performed detailed inspection of the
pleura, including all its recesses. With a shell-type biop-
sy forceps, specimens for histological examination were
taken from apparently malignant or suspect lesions. If
no suspicious lesions were found, multiple parietal biop-
sies were taken. Finally, the sclerosant agent was given,
according to randomization. To prevent rapid evacua-
tion of the agent in the doxycycline group, we suspend-
ed the connecting tube 30 cm above the level of the
patient’s chest; this technique allows evacuation of air
from the pleural cavity and lung re-expansion, which is,
in our opinion, safer than clamping the chest tube.
The patients were extubated in the OR and transferred
to the postoperative unit. Blood oxygen saturation, EKG,
blood pressure, temperature and volume of the fluid
drained were monitored, and the position of the patient
was changed every 15–20 minutes. We used the standard
criteria for chest tube removal: full lung reexpansion, no
air leak, and volume of the fluid drained ≤150 ml/24 h.
In the doxycycline group, if the volume of drainage
exceeded 150 ml/24 h, we administered the next 500 mg
dose, for a total amount of 3 doses, according to the
protocol described by Robinson at all [13]. A control chest
X-ray was performed the next day after videothora-
coscopy, before chest tube removal and on the next day,
before discharge of the patient and according to any spe-
cial indications. All complications were recorded.
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In the patients with advanced malignancy, all parame-
ters, both objective and subjective, deteriorate with
time, irrespective of success of pleurodesis. Thus the
only reliable criterion for the success of this procedure is
the absence of reaccumulation of pleural effusion. A
description of pleurodesis effects is shown in table 2.
The short-term and long-term effectiveness of pleu-
rodesis was assessed separately. As a short-term effect
we adopted the effectiveness after a single dose of talc
powder given during videothoracoscopy or after 1–3
doses of doxycycline. The criterion for long-term effec-
tiveness was no fluid reaccumulation until the death of
the patient, or – in the case of those who were still alive
at the moment of closing the study – for at least 12
months.
The efficiency of the procedure was analyzed using the
Mann-Whitney test, and a p-value of <0.05 was consid-
ered significant.
RESULTS
There were 33 patients analyzed: 18 in the talc group and
15 in the doxycycline group. In the talc group there were
4 men and 14 women; the mean age was 63 years (range
47–81). In the doxycycline group there were 2 men and
13 women; the mean age was 61 years (range 44–72).
The most common primary tumor in both groups was
breast cancer (16 patients), lung cancer (8 patients), and a
group of patients with unknown primary malignancy. In
the remaining group there were renal, endometrial, ovar-
ian and prostate carcinomas, lymphoma, myeloma and
malignant melanoma, one patient each. For the purpose
of statistical analysis they were included in one group.
The analysis showed no statistically significant differ-
ences between the talc and doxycycline group with
regard to the incidence of primary malignancy (p=0.14).
The analysis of advancement of metastatic disease in the
above mentioned original scale showed no statistically
significant differences between the talc and doxycycline
groups (p=0.55). Thus, both groups were comparable
in regard to age, sex and the most important variables
influencing effectiveness of the procedure.
The analysis of short-term effectiveness of pleurodesis
showed a highly significant difference in favor of talc
powder (p=0.009) (Figure 1); this difference was the
reason for terminating of the randomization.
Further observation revealed that the number of
patients with fluid reaccumulation in doxycycline group
was increasing with time; this was not observed in the
talc group. In the doxycycline group, of 7 patients with
excellent response to therapy only in one the effect
remained excellent until the end of observation (she
died 26 months after pleurodesis); in 3 cases, we
observed limited reaccumulation of fluid, not requiring
paracenthesis (they died after 4, 6 and 17 months) and
in 1 patient there was failure of pleurodesis after two
weeks. In the remaining 2 patients there were no avail-
able long-term data: one of them was lost to follow-up,
and the last died 3 days after the VTS due to respirato-
ry and circulatory insufficiency. Two patients in the
doxycyline group, in whom the results of pleurodesis
were initially good, maintained this effect until the end
of observation (one died at 2.5 months and the other
was still alive at the moment of final analysis, 15 months
after surgery).
In contrast to the increasing rate of pleurodesis failure
in the doxycycline group, only in one patient in the talc
group we observed limited reaccumulation of fluid in
the last month of her life, not requiring thoracentesis
(she died 20 months after pleurodesis). A statistical
analysis of the long-term effectiveness of both agents
studied showed a more significant difference in favor of
talc powder (p=0.00003) (Figure 2).
Independently of the above analysis, we attempted to
achieve talc pleurodesis in 6 patients in the doxycycline
group who failed to respond to treatment. One of them
died in the postoperative period due to respiratory
insufficiency, and in the remaining 5 cases we attempted
to achieve pleurodesis with 10 g of talc instilled as a
slurry via a chest tube. In 4 of these cases the result was
good (three died after 1.3, 5.3 and 10 months, and one
was still alive at the moment of final analysis, 21 months
after surgery). In the last patient the effect was excel-
lent: he was still alive at the moment of final analysis, 13
months after surgery. Thus, in all patients receiving talc
slurry as a second-line treatment, the result was good or
excellent.
DISCUSSION
Our results suggest that in patients with malignant
pleural effusion the primary sclerosant agent used for
pleurodesis should be talc (powder or slurry), because
of its highly superior effectiveness.
Excelent
Good
Poor
No fluid reaccumulation
Limited residual fluid, not increasing, no indications for
thoracentesis
Fluid reaccumulation requiring thoracentesis
Effect Description
Table 2. Description of pleurodesis outcome.
I
II
III
IV
Nodular metastases limited to the lower part of parietal
pleura
Nodular metastases occupying all the parietal pleura
Nodular metastases occupying parietal and visceral
pleura
Wide infiltration of parietal and visceral pleura, with lung
entrapment and multilocular fluid collections
Stage Type of involvement
Table 1. Staging of metastatic involvement of the pleura.
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Figure 1. Short-term results of pleurodesis in talc and doxycycline groups. P – poor, G – good, Ex – excellent.
Figure 2. Long-term results of pleurodesis in talc and doxycycline groups. P – poor, G – good, Ex – excellent.
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It has been shown that a malignancy is the most common
cause of pleural fluid accumulation [15–21], and the esti-
mated number of patients with malignant pleural effusion
may be as high as 100/100,000 population [22]. Such a
great incidence makes the malignant pleural effusion a
serious problem for health-care institutions. Involvement
of the pleura in metastatic disease usually makes curative
treatment impossible, and therefore the goal in these
patients is palliation of symptoms that may significantly
worsen the quality of their life. A number of methods have
been investigated in the treatment of malignant pleural
effusion, including repeated needle aspiration, continuous
pleural drainage (also in outpatients, with thin-bore
catheter and bag) [23–27], pleurectomy [2829], irradiation
of the chest [30], intrapleural chemotherapy [31,32],
chemoimmunotherapy [33], and intrapleural α-2b inter-
feron [34], TNF [35], and interleukin-2 [36]. Although
these methods may be indicated in certain clinical condi-
tions, the most commonly used in clinical practice is chem-
ical pleurodesis. This is because of the simplicity, safety
and effectiveness of this method. There are many agents
used to achieve pleurodesis, including tetracycline, doxy-
cycline, minocycline, bleomycin, cisplatin, doxorubicine,
vincristine, etoposide, 5-fluorouracil, interferon, mito-
mycine C, Corynebacterium parvum, methyloprednisolone,
talc, povidone-iodine, polidocanol, erythromycin,
mepacrine, and silver nitrate [1–13]. A great number of
papers have been published in the past two decades,
showing good effectiveness of talc and doxycycline
[32–45], but the differences of methods used make com-
parison difficult. In most of the studies the stage of
involvement of pleura in metastatic disease was not
recorded. The increasing popularity of videothoracoscopy
makes it possible to specify the stage, giving the opportu-
nity to design a study, assessing the real effectiveness of
sclerosing agents in comparable groups of patients.
The shortcoming of our study is undoubtedly the limited
number of patients analyzed. This was partly because of
the restrictive excluding criteria we adopted. However,
the impossibility of re-expansion of the lung makes pleu-
rodesis impossible, and we believe that including
patients with malignant pleural meosthelioma would
have biased the results. Malignant mesothelioma, being
in the pleura localized, not metastatic disease, is charac-
terised by different behavior; in selected patients there is
the possibility of curative treatment, consisting of radical
surgery and chemoradiotherapy. The significant num-
ber of patients with malignant mesothelioma in our
group (14 of 52) is due to the activity of an asbestos fac-
tory in our region (terminated two years ago).
Despite the smaller than initially planned number of
patients analyzed, making the assessment of events like
talc complications impossible, the study was able to
answer the main clinical question about the relative effi-
ciency of talc powder and doxycycline in achieving pleu-
rodesis in patients with malignant pleural effusion.
CONCLUSION
Talc powder is superior to doxycycline in achieving
pleurodesis in patients with malignant pleural effusion,
and the difference is statistically highly significant. Our
results suggest that the use of doxycycline for pleurode-
sis should be abandoned with the exception of non-
malignant diseases.
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